[{"id":"7bf35929-12d7-4980-addf-673178a01848","acronym":"CAR4SAR","url":"https://clinicaltrials.gov/study/NCT06087341","created_at":"2023-10-17T15:12:54.468Z","updated_at":"2024-07-02T16:35:09.876Z","phase":"Phase 1","brief_title":"A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma","source_id_and_acronym":"NCT06087341 - CAR4SAR","lead_sponsor":"Antonio Pérez Martínez","biomarkers":" NKG2D • ULBP2","pipe":"","alterations":" ","tags":["NKG2D • ULBP2"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/10/2024","start_date":" 01/10/2024","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-04-12"},{"id":"4ec6aa27-3db0-4988-ad1b-af35a4aa997e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05583201","created_at":"2022-10-17T13:56:08.698Z","updated_at":"2024-07-02T16:35:56.294Z","phase":"Phase 1","brief_title":"NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors","source_id_and_acronym":"NCT05583201","lead_sponsor":"jianming xu","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KD-496"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/13/2022","start_date":" 10/13/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-02-07"},{"id":"c8dca8c7-a482-4d7b-823f-95465ef1e767","acronym":"","url":"https://clinicaltrials.gov/study/NCT05131763","created_at":"2021-11-23T13:53:39.639Z","updated_at":"2024-07-02T16:36:20.316Z","phase":"Phase 1","brief_title":"NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors","source_id_and_acronym":"NCT05131763","lead_sponsor":"Fudan University","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KD-025 CAR T-cells"],"overall_status":"Recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2021-11-23"},{"id":"371d58a2-25f1-4a65-ae93-d66ba3aa87c2","acronym":"DEPLETHINK","url":"https://clinicaltrials.gov/study/NCT03466320","created_at":"2021-01-18T17:05:05.194Z","updated_at":"2024-07-02T16:36:30.744Z","phase":"Phase 1/2","brief_title":"DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2","source_id_and_acronym":"NCT03466320 - DEPLETHINK","lead_sponsor":"Celyad Oncology SA","biomarkers":" TP53 • NKG2D","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CYAD-01 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 09/18/2018","start_date":" 09/18/2018","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2021-05-04"},{"id":"a5b151fc-9227-45c1-95c7-a185934aa520","acronym":"","url":"https://clinicaltrials.gov/study/NCT04658004","created_at":"2021-01-19T20:41:58.819Z","updated_at":"2024-07-02T16:36:37.733Z","phase":"Phase 1","brief_title":"NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04658004","lead_sponsor":"Zhejiang University","biomarkers":" NKG2D","pipe":"","alterations":" ","tags":["NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NKG2D CAR T-cells"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 01/15/2027","study_completion_date":" 01/15/2027","last_update_posted":"2020-12-08"}]